Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.

Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, Zhong L, Cao W, Wen J, Feng W.

PLoS One. 2013 Apr 16;8(4):e61858. doi: 10.1371/journal.pone.0061858. Print 2013.

2.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. doi: 10.1016/j.canlet.2014.10.006. Epub 2014 Oct 8.

PMID:
25305453
3.

BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.

Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, Yu L.

Oncogene. 2014 Jan 2;33(1):44-54. doi: 10.1038/onc.2012.557. Epub 2012 Dec 3.

PMID:
23208504
4.

Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.

Kim JE, Yoon S, Choi BR, Kim KP, Cho YH, Jung W, Kim DW, Oh S, Kim DE.

Leukemia. 2013 Aug;27(8):1650-8. doi: 10.1038/leu.2013.60. Epub 2013 Feb 25.

PMID:
23434731
5.

Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.

Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.

Cancer Lett. 2015 May 1;360(2):245-56. doi: 10.1016/j.canlet.2015.02.031. Epub 2015 Feb 16.

PMID:
25697481
6.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

7.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

8.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

9.
10.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

11.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

12.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

13.

Grb10 is involved in BCR-ABL-positive leukemia in mice.

Illert AL, Albers C, Kreutmair S, Leischner H, Peschel C, Miething C, Duyster J.

Leukemia. 2015 Apr;29(4):858-68. doi: 10.1038/leu.2014.283. Epub 2014 Sep 24.

PMID:
25249015
14.

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.

Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.

Cancer. 2004 Apr 1;100(7):1459-71.

15.

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE.

Blood. 2003 Sep 15;102(6):2236-9. Epub 2003 May 15.

16.

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.

J Biol Chem. 2004 Aug 13;279(33):34227-39. Epub 2004 Jun 2.

17.

Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.

Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M, Umemura T.

Leuk Res. 2013 Oct;37(10):1278-86. doi: 10.1016/j.leukres.2013.07.019. Epub 2013 Aug 13.

PMID:
23953880
18.

Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.

Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.

Cancer Res. 2009 Dec 15;69(24):9337-45. doi: 10.1158/0008-5472.CAN-09-0548. Epub .

19.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

20.

Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.

Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, Yeung SC, Pan J.

Clin Cancer Res. 2012 Apr 1;18(7):1966-78. doi: 10.1158/1078-0432.CCR-11-1971. Epub 2012 Mar 23.

Items per page

Supplemental Content

Write to the Help Desk